首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices.
【24h】

Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices.

机译:系统性红斑狼疮患者血清APRIL水平升高:与疾病活动指数的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present study is to assess serum APRIL levels in SLE patients versus rheumatoid arthritis (RA) patients and normal control and to correlate serum APRIL levels in SLE patients with disease activity indices. Serum APRIL levels was measured in 40 SLE patients, 20 patients with RA and 20 healthy volunteers who served as control group. Disease activity in SLE patients was assessed by the British Isles Lupus Assessment Group (BILAG) index and SLE disease activity index (SLEDAI), and results were correlated with serum APRIL levels. Significantly higher serum APRIL levels was observed in SLE patients compared to RA patients and normal controls (p=0.003 and p < or = 0.001, respectively). Positive correlations were found between serum APRIL levels and total BILAG index (r=0.486 and p=0.001), BILAG musculoskeletal score (r=0.848 and p < or = 0.001) and BILAG cardiorespiratory score (r=0.326 and 0.04). Serum APRIL was higher in SLE patients compared to RA patients and normal control subjects and positively correlates with BILAG index and higher levels may be associated with musculoskeletal manifestations of the disease. APRIL antagonism could be a potential therapeutic target in SLE.
机译:本研究的目的是评估SLE患者与类风湿性关节炎(RA)和正常对照组的血清APRIL水平,并将SLE患者的血清APRIL水平与疾病活动指数相关联。在40例SLE患者,20例RA患者和20例健康志愿者(作为对照组)中测量了血清APRIL水平。 SLE患者的疾病活动性通过不列颠群岛狼疮评估组(BILAG)指数和SLE疾病活动性指数(SLEDAI)进行评估,结果与血清APRIL水平相关。与RA患者和正常对照组相比,SLE患者的血清APRIL水平明显更高(分别为p = 0.003和p <或= 0.001)。血清APRIL水平与总BILAG指数(r = 0.486和p = 0.001),BILAG肌肉骨骼评分(r = 0.848和p <或= 0.001)与BILAG心肺评分(r = 0.326和0.04)之间呈正相关。与RA患者和正常对照组相比,SLE患者的血清APRIL更高,并且与BILAG指数呈正相关,更高的水平可能与疾病的肌肉骨骼表现有关。 APRIL拮抗作用可能是SLE的潜在治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号